Despite the hoopla, the accuracy of CRISPR-based approaches has raised concerns among academics, clinicians and regulators. The ability to do single base corrections or conversions should help move the field forward. But I am more intrigued by the editing of RNA and the benefits of transient changes, option for scheduled or ad hoc retreatment, and how this technology mergers with the race for RNA therapeutics from Moderna and others.